Clinical trial · Interventional
Desensitizing Distressing Recollections in Cancer Patients
NCT02760524CI-TRIAL-00089251NETcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The major goal of this study is to determine whether Neuro-Emotional Technique is a viable treatment option for decreasing distress in cancer patients. The potential advantages of NET are: 1) it is designed specifically to address distressing stimuli and unresolved emotional memories; 2) it is a brief, time-limited intervention; and 3) its multi-modal design may appeal to and benefit a broader range of patients than a single mode intervention
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NET Intervention | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- Subjects will receive NET intervention treatment immediately
- interventionNames
- Behavioral: NET Intervention
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Subjects will receive NET intervention treatment and serve as a wait-list control
- interventionNames
- Behavioral: NET Intervention
Primary outcomes (3)
- measure
- Post traumatic Cognitions Inventory
- timeFrame
- baseline/ 4 weeks/6 months follow up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years of age * Distressing cancer-related recollection that has persisted for at least six months * Distressing cancer-related recollection that causes physiological reactivity (i.e., increased heart rate and/or increased skin conductance level - SCL), as described in section 4.2.3. * Received a cancer diagnosis at least 6 months prior to being contacted for participation in this study Exclusion Criteria: * Any current Major Mental Disorder, as assessed by Structured Clinical Interview for DSM IV Axis I Disorders (SCID - Clinical Version, First et al, 1997) * History of Post-traumatic Stress Disorder * Current active mood primary disorder prior to the cancer diagnosis (as per PI or designate) * History or current diagnosis of substance or alcohol abuse or dependence (as per PI or designate) * Use of psychotropic medications within the past month or current use of medications that would interfere with autonomic nervous system measures (benzodiazepines, barbiturates, major tranquilizers). * Use of some psychotropic medications are allowed such as SSRIs and certain sleep aids, but dosages must be stable from six weeks prior to enrollment and throughout study period * Any psychological or musculoskeletal problems that would interfere with psychophysiological assessments and treatment * Currently receiving chemotherapy or radiation * Are in the terminal stages of illness
References
Publications (0)
Data not yet available
No reference posted for this study.